Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

NxStage Medical Inc Issues Q2 2013 Guidance; Net Profit Below Analysts' Estimates; Reaffirms FY 2013 Guidance


Thursday, 2 May 2013 07:28am EDT 

NxStage Medical Inc announced that for the second quarter of 2013, it expects revenue to be in a range of $64.0-$65.5 million, net loss in the range of $4.0-$5.0 million or $(0.07)-$(0.08) per share. For fiscal 2013, it reaffirming both guidance. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $64.5 million, net profit of $(3.9) million, and EPS of $(0.07) for the second quarter of 2013; net profit of $(14) million, and EPS of $(0.24) for fiscal 2013. 

Company Quote

12.27
-0.065 -0.53%
4:00pm EDT